Accordion title open

Show Description

Accordion title close

Close Description

Composite Endpoint Results With Mounjaro vs Ozempic 1 mg

Figure depicting proportion of patients with a composite endpoint of A1C ≤6.5% + weight reduction ≥10% + no clinically significant or severe hypoglycemic events at 40 weeks. There were 470, 469, 469, and 468 patients in the Mounjaro 5 mg, 10 mg, 15 mg, and Ozempic 1 mg treatment groups, respectively, and 32%, 51%, 60%, and 22% of patients, respectively, had this composite endpoint at 40 weeks.